Search results for "biopharma" in Articles / App Notes
Article
Process Development: 2020 Reflections and 2021 Possibilities
Perspectives on Process Intensification
While continuous operations are the standard for many manufacturing industries, the move from batch to continuous bioprocessing has been slow across biophar…
Article
The Importance of Partnering for Bioanalytical Studies
Partnership benefits
BioPharm: Why is it important, or even necessary, for some biopharma companies to partner with an outsourcing partner for the purpose of bioanalytic studies?
Bose (Emery…
Article
Gene Therapies Push Viral Vector Production
“As with all new technologies in biopharma, there are several hurdles to take, but we follow the developments in the field closely and take along the lessons learned from other molecules.”
“Pl…
Article
2019’s Top Bioprocessing Trends and What to Expect in 2020
QbD, Regulatory, and Validation Considerations
Viral clearance is a topic on the minds of many in the biopharma industry, and for good reason. Considering the manufacturing challenges experienced …
Article
Supply Chain Challenges for Single-Use Systems
By Jennifer Markarian
The implementation of single-use systems (SUS) for biopharmaceutical manufacturing as an alternative to or in combination with traditional stainless-steel equipment o…
Article
CDMOs Driving Emerging Bio/Pharma Success
Analysts who track the industry expect 2018 to be the sixth straight year of substantial new investment in emerging biopharma companies from venture capital, public markets, and partnering. Funding fo…
Article
Roadmap Leads to Innovative Biomanufacturing Strategies
This staged integration was very much the right approach since it was the first time the biopharmaceutical industry came together to collaborate in the pre-competitive space. It took some time for the…
Article
Going Small to Achieve Success on the Commercial Scale
Challener
Biopharmaceutical manufacturing involves a series of complex unit operations linked together to provide high-purity, biologic actives with specified physicochemical and pharmacokinetic p…
Article
Taking a “Development-by-Design” Approach to Cell Therapies
A new CEO, David Mazzo, with a doctorate in analytical chemistry and experience running both private and public international biopharma companies, assumed NeoStem’s leadership in January. He sees no c…
Article
Pulling Out All the Stops in mAb Manufacturing
While the biopharma industry is pushing the barriers with antibody development, it must also contend with contemporary challenges in bulk monoclonal antibody (mAb) manufacturing. The need for…